Rare diseases
Investigational molecules
Locations
500 North Beacon Street Floor 4, 02472-5801, United States
Clinical research in moderate to severe atopic dermatitis focuses on inflammatory skin disease, with interest in symptom control, skin barrier dysfunction, and immune-driven disease activity.
The sponsor’s dermatology portfolio is centered on oral therapeutic approaches for patients with persistent disease burden.
Kymera Therapeutics Inc. runs clinical trials in conditions such as Asthma, Dermatitis atopic, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma
AustriaLong‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma
AustriaA Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis
CzechiaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
